MUMBAI, India, Sept. 7 -- Intellectual Property India has published a patent application (202617043730 A) filed by Act Biotherapeutics Corporation on April 06, 2026, for Anti-Nectin-4 Antibodies And Methods Of Use Thereof.
Inventors include Fonge, Humphrey; Uppalapati, Maruti; and Babeker, Hanan Esmail Ed.
The application for the patent was published on September 04, 2026, under issue no. 36/2026.
Abstract: Provided herein are antibodies which specifically binds Nectin-4 comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3, and the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3, wherein the CDR-L1 is SEQ ID NO: 1, CDR-L2 is amino acid sequence GA, and CDR-L3 is SEQ ID NO: 3, CDR-H1, CDR-H2, CDR-H3 are SEQ ID NOs 4-6, respectively; CDR-L1 is SEQ ID NO: 68, CDR-L2 is amino acid sequence DA, and CDR-L3 is SEQ ID NO: 70, CDR-H1, CDR-H2, CDR-H3 are SEQ ID NOs 71-73, respectively; or CDR-L1 is SEQ ID NO: 74, CDR-L2 is amino acid sequence AA, and CDR-L3 is SEQ ID NO: 76, CDR-H1, CDR- H2, CDR-H3 are SEQ ID NOs 77-79, respectively, and methods of use thereof.
Disclaimer: Curated by HT Syndication.
